The estimated Net Worth of Alan Seth Krasner is at least $4.09 Milione dollars as of 17 October 2023. Alan Krasner owns over 7,000 units of Crinetics Pharmaceuticals Inc stock worth over $2,547,655 and over the last 6 years he sold CRNX stock worth over $0. In addition, he makes $1,545,780 as Chief Medical Officer at Crinetics Pharmaceuticals Inc.
Alan has made over 3 trades of the Crinetics Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 7,000 units of CRNX stock worth $84,070 on 17 October 2023.
The largest trade he's ever made was exercising 7,000 units of Crinetics Pharmaceuticals Inc stock on 17 October 2023 worth over $84,070. On average, Alan trades about 1,744 units every 213 days since 2018. As of 17 October 2023 he still owns at least 50,210 units of Crinetics Pharmaceuticals Inc stock.
You can see the complete history of Alan Krasner stock trades at the bottom of the page.
Dr. Alan Seth Krasner M.D. serves as Chief Medical Officer of the Company. Dr. Krasner served as Global Clinical Development Lead at Shire plc, a global biotechnology company focused on the treatment of rare diseases. Before joining Shire, Dr. Krasner served from May 2008 to November 2015 as Chief Medical Officer for Biodel Inc., a specialty biopharmaceutical company focused on the treatment of diabetes. Prior to Biodel, from 2002 to 2008, Dr. Krasner served as Director in the Department of Clinical Research Metabolic Diseases at Pfizer Global Research and Development, where he was responsible for the design, execution, clinical analysis, and reporting of multiple, global clinical trials supporting registration of late stage drug candidates. Dr. Krasner served as a consulting physician at the Joslin Diabetes and Endocrinology Center of the Lawrence and Memorial Hospital in New London, Connecticut until July 2017. Dr. Krasner holds a B.S. from the Medical Education Honors Program at Northwestern University and a M.D. from Northwestern University Medical School. He completed his residency at Johns Hopkins Hospital in internal medicine and subsequently completed his fellowship at Johns Hopkins Hospital in endocrinology and metabolism.
As the Chief Medical Officer of Crinetics Pharmaceuticals Inc, the total compensation of Alan Krasner at Crinetics Pharmaceuticals Inc is $1,545,780. There are 1 executives at Crinetics Pharmaceuticals Inc getting paid more, with R. Scott Struthers having the highest compensation of $3,766,660.
Alan Krasner is 56, he's been the Chief Medical Officer of Crinetics Pharmaceuticals Inc since 2018. There are 9 older and 9 younger executives at Crinetics Pharmaceuticals Inc. The oldest executive at Crinetics Pharmaceuticals Inc is Wendall Wierenga, 72, who is the Independent Chairman of the Board.
Alan's mailing address filed with the SEC is C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG 2, SAN DIEGO, CA, 92121.
Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen e Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include: